Future Strategies for Mitigation and Treatment of Chronic Radiation-Induced Normal Tissue Injury

Seminars in Radiation Oncology

Volumn 17, Issue 2, 2007, Pages 141-148

  Moulder, John E ^a   Cohen, Eric P ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; PENTOXIFYLLINE; PLACEBO; RAMIPRIL; SPIRONOLACTONE; SUPEROXIDE DISMUTASE; TELMISARTAN; TEMOCAPRIL;

ARTICLE; BRAIN INJURY; CELL DEATH; CLINICAL TRIAL; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM CELL; HUMAN; KIDNEY DISEASE; KIDNEY INJURY; LUNG INJURY; MITOSIS; NONHUMAN; OXIDATIVE STRESS; PARENCHYMA; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION EXPOSURE; RADIATION INJURY; RADIATION PNEUMONIA; RADIATION PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL; TREATMENT PLANNING;

ACCIDENTS, RADIATION; HUMANS; OXIDATIVE STRESS; RADIATION INJURIES; RADIATION PROTECTION; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; RENIN-ANGIOTENSIN SYSTEM;

EID: 33947512453     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2006.11.010     Document Type: Article

References (95)

1. Moulder J.E. Pharmacological intervention to prevent or ameliorate chronic radiation injuries. Semin Radiat Oncol 13 (2003) 73-84
2. Stone H.B., McBride W.H., and Coleman C.N. Modifying normal tissue damage postirradiation. Radiat Res 157 (2002) 204-223
3. Moulder J.E. Post-irradiation approaches to treatment of radiation injuries in the context of radiological terrorism and radiation accidents: A review. Int J Radiat Biol 80 (2004) 3-10
4. Coleman C.N., Blakely W.F., and Fike J.R. Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection. Radiat Res 159 (2003) 812-834
5. Stone H.B., Moulder J.E., and Coleman C.N. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Radiat Res 162 (2004) 711-728
6. Moulder J.E., Fish B.L., and Cohen E.P. ACE inhibitors and AII receptor antagonists in the treatment and prevention of bone marrow transplant nephropathy. Curr Pharm Des 9 (2003) 737-749
7. Kim J.H., Brown S.L., and Kolozsvary A. Modification of radiation injury by Ramipril, inhibitor of angiotensin converting enzyme, on optic neuropathy in the rat. Radiat Res 161 (2004) 137-142
8. Cohen E.P., Hussain S., and Moulder J.E. Successful treatment of radiation nephropathy with angiotensin II blockade. Int J Radiat Oncol Biol Phys 55 (2003) 190-193
9. Delanian S., Porcher R., and Balla-Mekias S. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol 21 (2003) 2545-2550
10. Robbins M.E., and Diz D.I. Pathogenic role of the renin-angiotensin system in modulating radiation-induced late effects. Int J Radiat Oncol Biol Phys 64 (2006) 6-12
11. Cohen EP, Joines MM, Moulder JE: Prevention and treatment of radiation injuries-The role of the renin-angiotensin system. In Late Effects on Normal Tissues of Cancer Treatment, in Rubin P, Constine LS, Mark LB, Okunieff P (eds), Springer-Verlag, Heidelberg. (in press)
12. Robbins M.E.C., and Zhao W. Chronic oxidative stress and radiation-induced late normal tissue injury: A review. Int J Radiat Biol 80 (2004) 251-259
13. Langan A.R., Kahn M.A., and Yeung I.W.T. Partial volume rat lung irradiation: The protective/mitigating effects of Eukarion-189, a superoxide dismutase-catalase mimetic. Radiother Oncol 92 (2006) 231-238
14. Berger M.E., Christensen D.M., and Lowry P.C. Medical management of radiation injuries: current approaches. Occup Med 56 (2006) 162-172
15. Pellmar T.C., and Rockwell S. Priority list of research areas for radiological nuclear threat countermeasures. Radiat Res 163 (2005) 115-123
16. Moulder J.E., Fish B.L., and Cohen E.P. Treatment of radiation nephropathy with ACE inhibitors. Int J Radiat Oncol Biol Phys 27 (1993) 93-99
17. Moulder J.E., Fish B.L., and Cohen E.P. Brief pharmacologic intervention in experimental radiation nephropathy. Radiat Res 150 (1998) 535-541
18. Moulder J.E., Fish B.L., and Cohen E.P. Noncontinuous use of angiotensin converting enzyme inhibitors in the treatment of experimental bone marrow transplant nephropathy. Bone Marrow Transplant 19 (1997) 729-736
19. Geraci J.P., Sun M.C., and Mariano M.S. Amelioration of radiation nephropathy in rats by postirradiation treatment with dexamethasone and/or captopril. Radiat Res 143 (1995) 58-68
20. Moulder J.E., Robbins M.E.C., and Cohen E.P. Pharmacologic modification of radiation-induced late normal tissue injury. Cancer Treat Res 93 (1998) 129-151
21. Juncos L.I., Carrasco Dueñas S., and Cornejo J.C. Long-term enalapril and hydrochlorothiazide in radiation nephritis. Nephron 64 (1993) 249-255
22. Ward W.F., Molteni A., and Ts'ao C.H. Radiation pneumotoxicity in rats: Modification by inhibitors of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys 22 (1992) 623-625
23. Moulder J.E., Fish B.L., and Cohen E.P. Angiotensin II receptor antagonists in the prevention of radiation nephropathy. Radiat Res 146 (1996) 106-110
24. Oikawa T., Freeman M., and Lo W. Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 51 (1997) 164-172
25. Molteni A., Moulder J.E., and Cohen E.P. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol 76 (2000) 523-532
26. Cohen E.P., Fish B.L., and Moulder J.E. The renin-angiotensin system in experimental radiation nephropathy. J Lab Clin Med 139 (2002) 251-257
27. Robbins M.E.C., Campling D., and Rezvani M. Radiation nephropathy in mature pigs following the irradiation of both kidneys. Int J Radiat Biol 56 (1989) 83-98
28. Ward W.F., Kim Y.T., and Molteni A. Radiation-induced pulmonary endothelial dysfunction in rats: Modification by an inhibitor of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys 15 (1988) 135-140
29. Cohen E.P., and Robbins M.E.C. Radiation nephropathy. Semin Nephrol 23 (2003) 486-499
30. Rosenberg M.E., Smith L.J., and Correa-Rotter R. The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int 45 (1994) 403-410
31. Birkenhager W.H., and De Leeuw P.W. Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J Hypertens 17 (1999) 873-881
32. Siragy H.M., De Gasparo M., and El-Kersh M. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension 38 (2001) 183-186
33. De Paepe B., Verstraeten V.L.R.M., and De Potter C.R. Increased angiotensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression. Histochem Cell Biol 117 (2002) 13-19
34. 2 receptors. Kidney Int 61 (2002) 1986-1995
35. Ichihara S., Senbonmatsu T., and Price E. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 104 (2001) 346-351
36. 2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 31 (1998) 349-355
37. Moulder J.E., Fish B.L., and Cohen E.P. Impact of angiotensin II type 2 receptor blockade on experimental radiation nephropathy. Radiat Res 161 (2004) 312-317
38. Moulder JE, Fish BL, Cohen EP: Treatment of radiation nephropathy with ACE inhibitors and AII type-1 and type-2 receptor antagonists. Curr Pharm Des (in press)
39. Moulder J.E., Fish B.L., and Regner K.R. Retinoic acid exacerbates radiation nephropathy. Radiat Res 157 (2002) 199-203
40. Moulder J.E., Fish B.L., and Cohen E.P. Dietary sodium modification and experimental radiation nephropathy. Int J Radiat Biol 79 (2002) 903-911
41. Cohen E.P., Fish B.L., and Moulder J.E. The role of nitric oxide in radiation nephropathy. Arch Physiol Biochem 104 (1996) 200-206
42. Datta P.K., Moulder J.E., and Fish B.L. TGF-β1 production in radiation nephropathy: Role of angiotensin II. Int J Radiat Biol 75 (1999) 473-479
43. 1 and provides protection in mice with radiation-induced pulmonary fibrosis. Radiat Res 165 (2006) 546-552
44. Nishioka A., Ogawa Y., and Mima T. Histopathologic amelioration of fibroproliferative change in rat irradiated lung using soluble transforming growth factor-beta (TGF-β) receptor mediated by adenoviral vector. Int J Radiat Oncol Biol Phys 58 (2004) 1235-1241
45. Rabbani Z.N., Anscher M.S., and Zhang X. Soluble TGFβ type II receptor gene therapy ameliorates acute radiation-induced pulmonary injury in rats. Int J Radiat Oncol Biol Phys 57 (2003) 563-572
46. Vujaskovic Z., and Groen H.J.M. TGF-β, radiation-induced pulmonary injury and lung cancer. Int J Radiat Biol 76 (2000) 511-516
47. Moore A.F., Heiderstadt N.T., and Huang E. Selective inhibition of the renal angiotensin type 2 receptor increases blood pressure in conscious rats. Hypertension 37 (2001) 1285-1291
48. Zhu Y.C., Stauss H.M., and Bao G. Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors. Can J Physiol Pharmacol 73 (1995) 827-831
49. Araujo M.C., Melo R.L., and Cesari M.H. Peptidase specificity characterization of C- and N-terminal catalytic sites of angiotensin I-converting enzyme. Biochemistry 39 (2000) 8519-8525
50. Azizi M., Ezan E., and Nicolet L. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: A new marker of chronic angiotensin-converting enzyme inhibition. Hypertension 30 (1997) 1015-1019
51. Peng H., Carretero O.A., and Brigstock D.R. Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension. Hypertension 42 (2003) 1164-1170
52. Iwamoto N., Xano H.J., and Yoshioka T. Acetyl-seryl-aspartyl-lysyl-proline is a novel natural cell cycle regulator of renal cells. Life Sci 66 (2000) 221-226
53. Azizi M., Rousseau A., and Ezan E. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 97 (1996) 839-844
54. Delanian S., and Lefaix J.L. The radiation-induced fibroatrophic process: Therapeutic perspective via the antioxidant pathway. Radiother Oncol 73 (2004) 119-131
55. Brown N.J., Nakamura S., and Ma L. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58 (2000) 1219-1227
56. Jaggi J.S., Seshan S.V., and McDevitt M.R. Mitigation of radiation nephropathy after internal α-particle irradiation of kidneys. Int J Radiat Oncol Biol Phys 64 (2006) 1503-1512
57. Antignac C., Gubler M.C., and Leverger G. Delayed renal failure with extensive mesangiolysis following bone marrow transplantation. Kidney Int 35 (1989) 1336-1344
58. Turman M.A., Hammond S., and Grovas A. Possible association of retinoic acid with bone marrow transplant nephropathy. PediatrNephrol 13 (1999) 755-758
59. Fonck C., Cosyns J.P., and Goffin E. Glomerulopathie après radiotherapie métabolique pour insulinome métastatique. Néphrologie 21 (2000) 206
60. Raife T.J., and Lager D.J. Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects. Mayo Clinic Proc 77 (2002) 323-328
61. Vincent F., Costa M.A., and Rondeau E. Chronic renal failure: A nonmalignant late effect of allogeneic stem cell transplantation. Blood 102 (2003) 2695
62. Moulder J.E., and Cohen E.P. Radiation-induced multi-organ involvement and failure: The contribution of radiation effects on the renal system. Br J Radiol Suppl 27 (2005) 82-88
63. Ichida S., Okada K., and Itoh M. Bone marrow transplant nephropathy successfully treated with angiotensin-converting enzyme inhibitor. Clin Exp Nephrol 10 (2006) 78-81
64. 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. Leuk Lymphoma 43 (2002) 2125-2131
65. Haysom L., Ziegler D.S., and Cohn R.J. Retinoic acid may increase the risk of bone marrow transplant nephropathy. Pediatr Nephrol 20 (2005) 534-538
66. Craig J.I.O., Sheehan T., and Bell K. The haemolytic uraemic syndrome and bone marrow transplantation. Br Med J 295 (1987) 887
67. Cruz D.N., Perazella M.A., and Mahnensmith R.L. Bone marrow transplant nephropathy: A case report and review of the literature. J Am Soc Nephrol 8 (1997) 166-173
68. Radiation Therapy Oncology Group. RTOG-0123: A Phase II Randomized Trial With Captopril in Patients Who Have Received Radiation Therapy±Chemotherapy for Stage II-IIIB Non-Small Cell Lung Cancer, Stage I Central Non-Small Cell Lung Cancer, or Limited-Stage Small Cell Lung Cancer (2004) Philadelphia
69. Robbins M.E.C., Zhao W.L., and Davis C.S. Radiation-induced kidney injury: A role for chronic oxidative stress?. Micron 33 (2002) 133-141
70. Kang S.K., Rabbani Z.N., and Folz R.J. Overexpression of extracellular superoxide dismutase protects mice from radiation-induced lung injury. Int J Radiat Oncol Biol Phys 57 (2003) 1056-1066
71. Vujaskovic Z., Anscher M.S., and Feng Q.F. Radiation-induced hypoxia may perpetuate late normal tissue injury. Int J Radiat Oncol Biol Phys 50 (2001) 851-855
72. Poli G., and Parola M. Oxidative damage and fibrogenesis. Free Rad Biol Med 22 (1997) 287-305
73. Maier C.M., and Chan P.H. Role of superoxide dismutases in oxidative damage and neurodegenerative disorders. Neuroscientist 8 (2002) 323-334
74. Massy Z.A., and Nguyen-Khoa T. Oxidative stress and chronic renal failure: Markers and management. J Nephrol 15 (2002) 336-341
75. Locatelli F., Canaud B., and Eckardt K.U. Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol Dial Trans 18 (2003) 1272-1280
76. Kinnula V.L., and Crapo J.D. Superoxide dismutases in the lung and human lung diseases. Cardiovasc Res 167 (2003) 1600-1619
77. Clemens M.R., Ladner C., and Schmidt H. Decreased essential antioxidants and increased lipid hydroperoxides following high-dose radiochemotherapy. Free Radic Res Commun 7 (1989) 227-232
78. Arterbery V.E., Pryor W.A., and Jiang L. Breath ethane generation during clinical total body irradiation as a marker of oxygen-free-radical-mediated lipid peroxidation: A case study. Free Radic Res Commun 17 (1994) 569-576
79. Ueda T., Toyoshima Y., and Moritani T.L. Protective effect of dipyridamole against lethality and lipid peroxidation in liver and spleen of the ddY mouse after whole-body irradiation. Int J Radiat Biol 69 (1996) 199-204
80. Umegaki K., Sugisawa A., and Shin S.J. Different onsets of oxidative damage to DNA and lipids in bone marrow and liver in rats given total body irradiation. Free Radic Biol Med 31 (2001) 1066-1074
81. Jack C.I.A., Cottier B., and Jackson M.J. Indicators of free radical activity in patients developing radiation pneumonitis. Int J Radiat Oncol Biol Phys 34 (1996) 149-154
82. Tofilon P.J., and Fike J.R. The radioresponse of the central nervous system: A dynamic process. Radiat Res 153 (2000) 357-370
83. Choi A.M., and Alam J. Heme oxygenase-1: Function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am J Resp Cell Mol Biol 15 (1996) 9-19
84. Abraham N.G., and Kappas A. Heme oxygenase and the cardiovascular-renal system. Free Radic Biol Med 39 (2005) 1-25
85. Datta P.K., Moulder J.E., and Fish B.L. Induction of heme oxygenase-1 in radiation nephropathy: Role of angiotensin. Radiat Res 155 (2001) 734-739
86. Carpenter M., Epperly M.W., and Agarwal A. Inhalation delivery of manganese superoxide dismutase-plasmid/liposomes protects the murine lung from irradiation damage. Gene Ther 12 (2005) 685-693
87. Greenberger J.S., Epperly M.W., and Gretton J. Radioprotective gene therapy. Curr Gene Ther 3 (2003) 183-195
88. Rabbani Z.N., Anscher M.S., and Folz R.J. Overexpression of extracellular superoxide dismutase reduces acute radiation induced lung toxicity. BMC Cancer 5 (2005) 59
89. Doctrow S.R., Baudry M., and Huffman K. Salen Mn complexes: Multifunctional catalytic antioxidants protective in models for neurodegenerative diseases of aging. In: Sessler J.L., Doctrow S.R., and McMurray J.T. (Eds). Medicinal Inorganic Chemistry (2004), American Chemical Society, New York 319-347
90. Lefaix J.L., Delanian S., and Leplat J.J. Successful treatment of radiation-induced fibrosis using Cu/Zn-SOD and Mn-SOD: An experimental study. Int J Radiat Oncol Biol Phys 35 (1996) 305-312
91. Delanian S., Baillet F., and Huart J. Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: Clinical trial. Radiother Oncol 32 (1994) 12-20
92. Lefaix J.L., Delanian S., and Vozenin M.C. Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and α-tocopherol: An experimental study. Int J Radiat Oncol Biol Phys 43 (1999) 839-847
93. Delanian S. Striking regression of radiation-induced fibrosis by a combination of pentoxifylline and tocopherol. Br J Radiol 71 (1998) 892-894
94. Food and Drug Administration. New drug and biological drug products: evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Fed Regist 67 (2002) 37988-37998
95. Food and Drug Administration. Good laboratory practice for non-clinical laboratory studies. 21 Code of Federal Register Part 58 (2002)